RealFeedApp beta
- Eurofins developed over 100 ADCs for clinical trials
ADC development remains complex and empirical, requiring linker chemistry, DAR, and stability optimization. Eurofins Discovery offers specialized linker synthesis for clinical trials.
- Field
- drugs and trials
- What they did
- Antibody-drug conjugates (ADCs) combine the precision of antibodies with the therapeutic power of small molecules to target cancer cells specifically, yet their development remains complex and requires careful optimization of chemical linkers.
- Why it matters
- This is crucial for advancing cancer treatments, as over 100 ADCs are currently in clinical development and have received numerous FDA approvals.
#adc#linker chemistry#bioconjugation#eurofins discovery#clinical trial
